Schedule of Ordinary Shares that were Excluded from the Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders (Details) - shares	6 Months Ended	12 Months Ended
Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Chemomab Therapeutics Ltd [Member] \| Share-Based Payment Arrangement, Option [Member]
Outstanding options to purchase ordinary shares and RSAs	40,589,680	44,471,160	41,564,080	38,494,200	29,873,100

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration